Key Summary
- GLP-1 medicines can help people lose significant weight, but benefits often fade if treatment stops.
- Rising obesity rates are driven more by food systems, marketing, and lifestyle environments than individual choice.
- Healthier food, active living, and better environments deliver broader, long-term benefits for everyone — beyond what medication alone can achieve.
A European study on obesity has said that weight-loss medications can improve individual outcomes, but it cannot lower population-level risk or deliver the wider societal, environmental, and economic benefits of obesity prevention.
The study titled, ‘The case for primary prevention of obesity in the era of GLP-1 therapies,’ published in Lancet Regional Health - Europe, has stated that medicines like GLP-1 receptor agonists has transformed treatment, leading to significant weight loss and metabolic benefits for many.
But this has shifted public and policy discourse, with some suggesting that effective treatment reduces the urgency of prevention, as if “obesity were now primarily a clinical rather than a societal challenge.”
The study noted that obesity prevalence continues to rise in most European countries and they do not reflect a lack of willpower among individuals, as generally thought, “but rather the structural and commercial forces that shape our environments and behaviours.”
It blames the modern food system that “produces an abundance of inexpensive ultra-processed, energy-dense, nutrient poor products, environmental and ecological degradation while marketing practices drive overconsumption; and urban design often discourages physical activity, encourages sedentary behaviours and disconnects with nature.”
The GLP-1 receptor agonists drugs (including semaglutide and tirzepatide) have proven effective for short-term weight reduction and improvement of metabolic parameters in large subgroups.
“While long-term data are still emerging, current evidence suggests that sustained benefits depend on continued treatment. They are still, without question, a major therapeutic advance.”
As obesity happens to be a relapsing disease, any discontinuation of the drug could have debilitating effects.
A recent study by Cambridge University had stated people on obesity jabs regain most of the weight they lose within a year of stopping the drugs. The researchers had warned that if the regained weight is mainly fat, they could "be worse off than before".
The study argues that policies that promote healthy diets, physical activity, and equitable access to supportive environments yield broad benefits. Apart from obesity, they also reduce cardiovascular disease, diabetes, and some types of cancer.
It also pointed out that preventive environments help even those who have lost weight through medicines. They support healthy food purchases, active transport (walking and cycling) in an equitable way; crucial for long-term maintenance of a healthy body composition.
It may be recalled that England's chief medical officer Prof Sir Chris Whitty had recently stated that he is against the public’s dependence on weight loss drugs, and instead supports restricting junk food advertisements and practicing a healthy diet.
He had said the weight loss drugs are "transformational" for people who need them, but this should be "a very small minority". But letting people become obese and then medicating them for life would not be the right course to take, he added.
